Beacon Therapeutics reported topline Phase 2/3 results for laruparetigene zovaparvovec, a subretinal gene therapy for X-linked retinitis pigmentosa, with 31.0% of high-dose and 24.1% of low-dose participants gaining at least 15 letters in low luminance visual acuity at 12 months versus none in untreated controls. Adverse events were predominantly mild to moderate and largely attributed to the surgical delivery procedure. The result represents durable functional recovery in a degenerative retinal disease previously considered irreversible.
Key Points
- 31% of high-dose patients gained 15+ letters in low-light acuity
- No untreated control participants reached the primary endpoint
- Adverse events mostly mild, largely tied to subretinal surgery
Longevity Analysis
Correcting a single inherited defect in photoreceptor maintenance halted and partially reversed progressive neural tissue loss, extending the functional lifespan of an organ that ordinarily only degrades. Low luminance acuity and microperimetry served as the decisive readouts here, illustrating how endpoint selection determines whether a genuine biological effect is detected or missed in slow-moving degenerative disease. As one-time genetic interventions move from rare disease into broader application, the operative questions shift toward durability of expression, the immune consequences of viral vector delivery, and how early in a degenerative trajectory such repair must be initiated to preserve tissue worth rescuing.
Original published by LT Wire.